Thoughtful, Targeted Research for Alzheimer’s and Dementia Patients
We’re creating novel operational approaches to shape a whole new – more rigorous – future for cognition research.
DEDICATED AND COMMITTED TEAM
Our experienced Alzheimer’s and Dementia team will make it clear why our clients come back again and again. Our project managers, physicians, statisticians, supply chain managers, central laboratory techs, and operations experts keep a laser focus on the holistic goal—improved patient health—from start to finish. We engage key opinion leaders and regulatory advisors early and often. And we work hard to make each study an experience we’d be proud to offer our own loved ones if they needed it.
NATALIA DROSOPOULOU, PHD
VICE PRESIDENT, PROJECT MANAGEMENT, NEUROSCIENCE
Natalia has worked in clinical research for nearly 25 years, focusing primarily on neurology, psychiatry, pain, and pediatrics. Her experience includes small, intricate Phase I studies as well as large global Phase III programs. As Franchise Area Lead for Neuroscience, she provides operational oversight to neuroscience projects, working with bespoke teams to develop operational strategy and to mitigate risk.
TOM BABIC, MD, PHD
VICE PRESIDENT, SCIENTIFIC SOLUTIONS, NEUROSCIENCE
Tom is a therapeutic leader in neurology medical and scientific affairs, with experience in both industry and academia. Tom is a board-certified neurologist and affiliate professor of clinical neurology. At Worldwide, he is responsible for the scientific and medical leadership of global neurology clinical research initiatives. He is involved with protocol design and development and clinical analysis for randomized controlled clinical trials in populations with early and advanced Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, epilepsy, stroke, migraine, and neurodegenerative disorders. He works to implement up-to-date, evidence-based science across Worldwide’s portfolio of clinical drug research and development projects.
PAULA PENNEY
EXECUTIVE DIRECTOR, PROJECT MANAGEMENT, ALZHEIMER’S DISEASE AND OTHER DEMENTIAS
Paula’s 20 years in the clinical research industry include both CRO and sponsor experience. Paula has managed and provided operational oversight for multifunctional teams on global and domestic projects across Phase I-IV programs in a wide variety of therapeutic areas, with neuroscience being her passion (including Alzheimer’s disease, schizoaffective disorder, bipolar disease with major depression, MCI, and dementia with Lewy bodies). Prior to her career in the clinical research industry, Paula was a critical care multidisciplinary nursing team lead in a busy Toronto hospital—giving her a keen awareness of the patient experience.
STEPHEN COATES
EXECUTIVE DIRECTOR, PROJECT MANAGEMENT, ALZHEIMER’S DISEASE AND OTHER DEMENTIAS
Stephen nurtures engagement within the CNS team at Worldwide to ensure operational excellence across dementia programs. He began his journey in the industry in 1998. Stephen progressed through the ranks from Clinical Research Associate through study management, building a strong portfolio of therapeutic experience before focusing on Alzheimer’s disease and dementia. Having worked for Roche, GSK, Pfizer, Takeda, Kendle and Covance, Stephen joined Worldwide in 2015.
Project teams experienced in dementias—including the Cognitive Task Force Team
Our expert advisors have undisputed medical, scientific, and operational experience in Alzheimer’s disease and other dementias. Our professionals participate in everything from Alzheimer’s disease Assessment Scale (ADAS) development of a Cognitive Task Force for large trials, which helps meet enrollment goals faster, save millions, and improve site, PI and KOL interactions.
Site relationships around the globe
Worldwide has built a global network of leading investigators and consultants for the past 40+ years. We’ve taken our time to cultivate the best locations for neuroscience imaging, CSF & biomarker studies, and dementia substudies.
Compound experience unlike anyone else
Our teams include neuropsychologists and neuroimaging experts who have contributed to the development of every drug class applicable to dementia diseases in the past 30 years. We have worked with all types of compounds,—so there’s nothing we can’t handle.
Integrated rater training and patient data quality support for clinical assessment technologies
Worldwide is one of the few full-service CROs that can provide integrated rater training, scale management, and management of electronic Clinical Outcome Assessments (eCOA) vendors. Our expertise unites patient experience and practical designs with rigorous data that position trials for success.
Extra support offers a major advantage in a crowded research indication
Most drug programs in Alzheimer’s and dementia research could benefit from an extensive array of cognition-focused teams ready to apply their knowledge amassed over the past four decades in the neuroscience field. When you work with Worldwide, that’s what you get—a host of experts engaged with you, from site staff all the way through our senior leadership—ready to make your program a success.
Neuroscience Experience
- Our Cognitive Task Force and scale development work speak volumes about our commitment to Alzheimer’s and Dementia research. At Worldwide, we design and execute rigorous, compassionate studies we’d be happy to have our own family and friends take part in, carefully protecting the patient experience and maintaining compelling data integrity to get products to market even in this competitive research space.
Worldwide was founded to help improve research for neurology patients. Decades later, we’ve done it all, working on a dizzying number of compounds and indications in every phase. Now Worldwide is one of the few full-service CROs that provides integrated rater training, scale management, bespoke assessment development, and a broad range of other highly specialized consulting services in addition to our top-notch global network of study execution experts.
Learn MoreWorldwide leads the way in best practice development for pain and addiction research. We have seen it all, which helps us offer the right blend of tried-and-true logistics, creative study designs, and thoughtful outcomes measures to augment objectivity in this otherwise nebulous field of research.
Learn MoreRare neurological diseases each have unique hurdles for developing compelling outcomes assessments that can demonstrate efficacy with small patient populations. Worldwide is a leader in rare disease recruitment, novel endpoint development, and innovative study designs. We deliver specialty studies that apply our overarching knowledge in neurological conditions and rare diseases to thoughtful study designs, respecting patient communities and generating the data sponsors need to advance their compound to market.
Learn MoreA crowded research space makes it difficult to weed the subjectivity out of the science—which demands a CRO with psychiatry know-how from the ground up and the top down. Our proven track record for patient recruitment and engaged investigator networks speaks volumes about our expertise in psychiatric trial development and execution.
Learn MoreWe’ve been a part of industry-sponsored psychedelic trials since they began. Our Psychedelic Center of Excellence has a comprehensive approach to the complex operational delivery of these trials and working with patients and sites for study success.
LEARN MOREOur Team of Neuroscience Functional Experts
Barry Dussault
Executive Director, Project Management, Franchise Area Lead, Analgesia, Addiction, and Neurology Rare Disorders
